| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2013 | US20130029955 Inhibitors of galectin-3 and methods of use thereof |
| 01/31/2013 | US20130029954 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors |
| 01/31/2013 | US20130029953 Progesterone antagonists |
| 01/31/2013 | US20130029952 Combination of Azelastine and Mometasone for Nasal Administration |
| 01/31/2013 | US20130029951 Combination of Azelastine and Ciclesonide for Nasal Administration |
| 01/31/2013 | US20130029950 Methods and compositions for the treatment of proliferative vascular disorders |
| 01/31/2013 | US20130029949 Substituted Quinolines and Their Use As Medicaments |
| 01/31/2013 | US20130029948 Heterocyclic autotaxin inhibitors and uses thereof |
| 01/31/2013 | US20130029947 Progesterone containing oral dosage forms and kits |
| 01/31/2013 | US20130029946 Dissolution of arterial plaque |
| 01/31/2013 | US20130029945 Darunavir Polymorph and Process for Preparation Thereof |
| 01/31/2013 | US20130029944 Inhibitors of protein kinases |
| 01/31/2013 | US20130029943 Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries |
| 01/31/2013 | US20130029942 Compounds and therapeutical uses thereof |
| 01/31/2013 | US20130029941 7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors |
| 01/31/2013 | US20130029940 Phosphonates with reduced toxicity for treatment of viral infections |
| 01/31/2013 | US20130029939 Novel glucokinase activators and methods of using same |
| 01/31/2013 | US20130029938 Chemical Compounds |
| 01/31/2013 | US20130029937 Treatment of surfactants |
| 01/31/2013 | US20130029936 Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same |
| 01/31/2013 | US20130029935 Mineral amino acid polysaccharide complex |
| 01/31/2013 | US20130029934 Silyl-derivatives of polysaccharides |
| 01/31/2013 | US20130029931 Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol with anti-tumor activity and preparation method thereof |
| 01/31/2013 | US20130029930 Activation and activators of sirt6 |
| 01/31/2013 | US20130029929 Nucleoside phosphoramidate prodrugs |
| 01/31/2013 | US20130029928 Compositions comprising perfluorooctanoic acid |
| 01/31/2013 | US20130029927 Combination of lbh589 with other therapeutic agents for treating cancer |
| 01/31/2013 | US20130029926 Compositions and methods for determing cancer susceptibility |
| 01/31/2013 | US20130029925 Method for Preventing Cancer Metastasis |
| 01/31/2013 | US20130029924 Glycosylated valproic acid analogs and uses thereof |
| 01/31/2013 | US20130029923 Materials and Methods for Prevention and Treatment of Viral Infections |
| 01/31/2013 | US20130029922 Formulations from natural products, turmeric, paclitaxel, and aspirin |
| 01/31/2013 | US20130029921 Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof |
| 01/31/2013 | US20130029919 Two part formulation system for opthalmic delivery |
| 01/31/2013 | US20130029918 Methods for reducing vein irritation |
| 01/31/2013 | US20130029902 Cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide |
| 01/31/2013 | US20130029901 Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| 01/31/2013 | US20130029900 Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| 01/31/2013 | US20130029846 Fungicidal Iminoderivatives |
| 01/31/2013 | US20130029845 Isoxazolines for controlling invertebrate pests |
| 01/31/2013 | US20130028992 Herbal-Based Solution for Treating Symptoms of Nasal Conditions |
| 01/31/2013 | US20130028989 Materials and method for inhibiting replication protein a and uses thereof |
| 01/31/2013 | US20130028986 Pharmaceutical Compositions |
| 01/31/2013 | US20130028980 Cell-polymer fiber compositions and uses thereof |
| 01/31/2013 | US20130028978 Compositions and methods for wound treatment |
| 01/31/2013 | US20130028977 Pharmaceutical powder composition for inhalation |
| 01/31/2013 | US20130028974 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 01/31/2013 | US20130028972 Tamper-resistant tablet providing immediate drug release |
| 01/31/2013 | US20130028971 Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections |
| 01/31/2013 | US20130028970 Tamper-resistant tablet providing immediate drug release |
| 01/31/2013 | US20130028969 Method for stable and controlled delivery of (-)-hydroxycitric acid |
| 01/31/2013 | US20130028967 Therapeutic agent for pulmonary fibrosis |
| 01/31/2013 | US20130028966 Broad Spectrum Antiviral and Antiparasitic Agents |
| 01/31/2013 | US20130028965 NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION |
| 01/31/2013 | US20130028964 NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION |
| 01/31/2013 | US20130028963 Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents |
| 01/31/2013 | US20130028962 Triggered Cargo Release from Nanoparticle Stabilized Liposomes |
| 01/31/2013 | US20130028961 Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| 01/31/2013 | US20130028960 Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
| 01/31/2013 | US20130028958 Beta-carbolines for use in the treatment of hearing loss and vertigo |
| 01/31/2013 | US20130028957 Pharmaceutical composition for treating cancer |
| 01/31/2013 | US20130028956 Method for preventing or treating memory impairment and pharmaceutical compositions useful therefore |
| 01/31/2013 | US20130028955 Sustained release oral matrix and methods of making thereof |
| 01/31/2013 | US20130028953 Transdermal Delivery Systems for Sufentanil |
| 01/31/2013 | US20130028947 Pharmaceutical composition for topical application |
| 01/31/2013 | US20130028946 Relating to antiviral compositions |
| 01/31/2013 | US20130028945 Novel composition for treatment of essential thrombocythemia |
| 01/31/2013 | US20130028944 Novel methods for targeting cancer stem cells |
| 01/31/2013 | US20130028943 Melatonin tablet and methods of preparation and use |
| 01/31/2013 | US20130028938 Solid pharmaceutical dosage form |
| 01/31/2013 | US20130028937 Co-crystals of venlafaxine and celecoxib |
| 01/31/2013 | US20130028927 Method of diagnosing and treating melioidosis |
| 01/31/2013 | US20130028921 Composition comprising coumestrol or a bean extract containing coumestrol |
| 01/31/2013 | US20130028912 Tweak/fn14 system regulates skeletal muscle atrophy and regeneration |
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028902 Osteocalcin as a treatment for male reproductive disorders |
| 01/31/2013 | US20130028899 Treatment of cancer by inhibiting activity or expression of late sv-40 factor |
| 01/31/2013 | US20130028896 Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses |
| 01/31/2013 | US20130028895 Exosome inhibiting agents and uses thereof |
| 01/31/2013 | US20130028889 Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| 01/31/2013 | US20130028887 Phenylacetic acid compound |
| 01/31/2013 | US20130028886 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 01/31/2013 | US20130028885 Methods to predict and prevent resistance to taxoid compounds |
| 01/31/2013 | US20130028883 Treatment of ischemic episodes and cerebroprotection through Misoprostol |
| 01/31/2013 | US20130028882 Antiviral compositions and methods of their use |
| 01/31/2013 | US20130028876 Thymidine kinase |
| 01/31/2013 | US20130028869 Feed supplement comprising oligosaccharides and medium chain fatty acids |
| 01/31/2013 | US20130028865 Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside |
| 01/31/2013 | US20130028863 Promyelocytic leukemia protein as a redox sensor |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | US20130028859 Hepatitis C Virus Inhibitors |
| 01/31/2013 | US20130028854 Osmoprotective Complexes for Prevention of Mitochondrial Free Radical Damage Related Skin Aging |
| 01/31/2013 | US20130028850 Topical tetracycline compositions |
| 01/31/2013 | US20130028848 Method of inhibiting harmful microorganisms and barrier-forming composition therefor |
| 01/31/2013 | US20130028845 Levalbuterol salt |
| 01/31/2013 | US20130028844 Preparations for effervescent formulations comprising cephalosporin and uses thereof |
| 01/31/2013 | US20130028843 Kallikrein 7 modulators |
| 01/31/2013 | US20130028837 Contrast agents for myocardial perfusion imaging |
| 01/31/2013 | DE202012001752U1 Zusammensetzung für die topische Behandlung A composition for the topical treatment |
| 01/31/2013 | DE102011108762A1 Verpresste feste pharmazeutische Zusammensetzung, umfassend amorphes partikuläres Valsartan als Wirkstoff Compressed solid pharmaceutical composition comprising amorphous particulate valsartan as active ingredient |